The Latest Breaking News from Pfizer

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Axios · Mar 31, 2022

FDA approves second shot for 50+

The authorization for another booster arrives just as BA.2 becomes the dominant strain in the U.S.

Salon · Mar 30, 2022

Opinion: How Shanghai Can Pioneer a New Path for Disease Control

Amid worst Covid-19 outbreak, city could turn pandemic into manageable endemic disease using self-isolation, self-testing and advanced drugs and vaccines

Caixin Global · Mar 30, 2022

Commentary: There is much we still don’t know about giving 5- to 11-year-olds a COVID-19 vaccine

Should children ages 5 to 11 receive the COVID-19 vaccine? This is a difficult question without an easy answer, something you wouldn’t know from the strident opinions of politicians and health experts.

Chicago Tribune · Mar 30, 2022

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service · Mar 29, 2022

Infectious omicron BA.2 now dominant in US, with coronavirus spring rise likely

LOS ANGELES — The highly infectious BA.2 omicron subvariant is now the dominant version of the coronavirus circulating in the United States, according to federal estimates, a development that is triggering fresh concerns of a potential springtime wave.

Los Angeles Times · Mar 29, 2022

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

Benzinga · Mar 29, 2022

LV=’s on board with £511,000 bonus for boss despite shambles of failed sale

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

The Guardian - UK · Mar 29, 2022

US regulators approve 2nd COVID booster for those aged 50 and up

US has seen a small uptick in new COVID-19 cases over the past week, raising concern that infections could surge again.

Al Jazeera · Mar 29, 2022

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ: 

Benzinga · Mar 29, 2022